Data Insights

CD70 CAR-T cells by Chongqing Precision Biotech for Gynecological Cancer: Likelihood of Approval

CD70 CAR-T cells is under clinical development by Chongqing Precision Biotech and currently in Phase I for Gynecological Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - CD70 CAR-T Cells in Gynecological Cancer

Data Insights

MC-150 by Chongqing Precision Biotech for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

MC-150 is under clinical development by Chongqing Precision Biotech and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - MC-150 in Primary Mediastinal B-Cell Lymphoma

Data Insights

Gene Therapy to Target CD19 for Oncology by Chongqing Precision Biotech for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Gene Therapy to Target CD19 for Oncology is under clinical development by Chongqing Precision Biotech and currently in Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target CD19 For Oncology in Diffuse Large B-Cell Lymphoma

Data Insights

Gene Therapy to Target CD19 for Oncology by Chongqing Precision Biotech for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Gene Therapy to Target CD19 for Oncology is under clinical development by Chongqing Precision Biotech and currently in Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target CD19 For Oncology in Chronic Lymphocytic Leukemia (CLL)

Data Insights

MC-150 by Chongqing Precision Biotech for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

MC-150 is under clinical development by Chongqing Precision Biotech and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell...

Likelihood of Approval and Phase Transition Success Rate Model - MC-150 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

MC-150 by Chongqing Precision Biotech for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

MC-150 is under clinical development by Chongqing Precision Biotech and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MC-150 in B-Cell Non-Hodgkin Lymphoma

Data Insights

MC-150 by Chongqing Precision Biotech for Follicular Lymphoma: Likelihood of Approval

MC-150 is under clinical development by Chongqing Precision Biotech and currently in Phase II for Follicular Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MC-150 in Follicular Lymphoma

Data Insights

MC-150 by Chongqing Precision Biotech for Mantle Cell Lymphoma: Likelihood of Approval

MC-150 is under clinical development by Chongqing Precision Biotech and currently in Phase II for Mantle Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MC-150 in Mantle Cell Lymphoma

Data Insights

MC-150 by Chongqing Precision Biotech for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

MC-150 is under clinical development by Chongqing Precision Biotech and currently in Phase II for Diffuse Large B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - MC-150 in Diffuse Large B-Cell Lymphoma

Data Insights

MC-150 by Chongqing Precision Biotech for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

MC-150 is under clinical development by Chongqing Precision Biotech and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - MC-150 in Chronic Lymphocytic Leukemia (CLL)

Data Insights

CD19 Targeted CAR-T Therapy by Chongqing Precision Biotech for Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Likelihood of Approval

CD19 Targeted CAR-T Therapy is under clinical development by Chongqing Precision Biotech and currently in Phase I for Granulomatosis with...

Likelihood of Approval and Phase Transition Success Rate Model - CD19 Targeted CAR-T Therapy in Granulomatosis with Polyangiitis (Wegener's Granulomatosis)

Data Insights

CD19 Targeted CAR-T Therapy by Chongqing Precision Biotech for Dermatomyositis: Likelihood of Approval

CD19 Targeted CAR-T Therapy is under clinical development by Chongqing Precision Biotech and currently in Phase I for Dermatomyositis. According...

Likelihood of Approval and Phase Transition Success Rate Model - CD19 Targeted CAR-T Therapy in Dermatomyositis

Data Insights

CD19 Targeted CAR-T Therapy by Chongqing Precision Biotech for Sicca Syndrome (Sjogren): Likelihood of Approval

CD19 Targeted CAR-T Therapy is under clinical development by Chongqing Precision Biotech and currently in Phase I for Sicca Syndrome...

Likelihood of Approval and Phase Transition Success Rate Model - CD19 Targeted CAR-T Therapy in Sicca Syndrome (Sjogren)

Data Insights

CD19 Targeted CAR-T Therapy by Chongqing Precision Biotech for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis): Likelihood of Approval

CD19 Targeted CAR-T Therapy is under clinical development by Chongqing Precision Biotech and currently in Phase I for Anti-Neutrophil Cytoplasmic...

Likelihood of Approval and Phase Transition Success Rate Model - CD19 Targeted CAR-T Therapy in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis)

Data Insights

CD19 Targeted CAR-T Therapy by Chongqing Precision Biotech for Systemic Sclerosis (Scleroderma): Likelihood of Approval

CD19 Targeted CAR-T Therapy is under clinical development by Chongqing Precision Biotech and currently in Phase I for Systemic Sclerosis...

Likelihood of Approval and Phase Transition Success Rate Model - CD19 Targeted CAR-T Therapy in Systemic Sclerosis (Scleroderma)

Data Insights

CD19 Targeted CAR-T Therapy by Chongqing Precision Biotech for Systemic Lupus Erythematosus: Likelihood of Approval

CD19 Targeted CAR-T Therapy is under clinical development by Chongqing Precision Biotech and currently in Phase II for Systemic Lupus...

Likelihood of Approval and Phase Transition Success Rate Model - CD19 Targeted CAR-T Therapy in Systemic Lupus Erythematosus

Data Insights

CD123-targeted CAR-NK by Chongqing Precision Biotech for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

CD123-targeted CAR-NK is under clinical development by Chongqing Precision Biotech and currently in Phase II for Relapsed Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - CD123-targeted CAR-NK in Relapsed Acute Myeloid Leukemia

Data Insights

Gene Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia by Chongqing Precision Biotech for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Gene Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia is under clinical development by Chongqing Precision Biotech...

Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target CD123 For Relapsed And Refractory Acute Myeloid Leukemia in Relapsed Acute Myeloid Leukemia

Data Insights

Gene Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia by Chongqing Precision Biotech for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Gene Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia is under clinical development by Chongqing Precision Biotech...

Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target CD123 For Relapsed And Refractory Acute Myeloid Leukemia in Refractory Acute Myeloid Leukemia

Data Insights

CD123-targeted CAR-NK by Chongqing Precision Biotech for Refractory Acute Myeloid Leukemia: Likelihood of Approval

CD123-targeted CAR-NK is under clinical development by Chongqing Precision Biotech and currently in Phase II for Refractory Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - CD123-targeted CAR-NK in Refractory Acute Myeloid Leukemia